Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats

Vaccine
Myra N WidjojoatmodjoHanneke Schuitemaker

Abstract

RSV is an important cause of lower respiratory tract infections in children, the elderly and in those with underlying medical conditions. Although the high disease burden indicates an urgent need for a vaccine against RSV, no licensed RSV vaccine is currently available. We developed an RSV vaccine candidate based on the low-seroprevalent human adenovirus serotypes 26 and 35 (Ad26 and Ad35) encoding the RSV fusion (F) gene. Single immunization of mice with either one of these vectors induced high titers of RSV neutralizing antibodies and high levels of F specific interferon-gamma-producing T cells. A Th1-type immune response was indicated by a high IgG2a/IgG1 ratio of RSV-specific antibodies, strong induction of RSV-specific interferon-gamma and tumor necrosis factor-alpha cytokine producing CD8 Tcells, and low RSV-specific CD4 T-cell induction. Both humoral and cellular responses were increased upon a boost with RSV-F expressing heterologous adenovirus vector (Ad35 boost after Ad26 prime or vice versa). Both single immunization and prime-boost immunization of cotton rats induced high and long-lasting RSV neutralizing antibody titers and protective immunity against lung and nasal RSV A2 virus load up to at least 30 weeks after i...Continue Reading

References

Jul 1, 1977·The Journal of General Virology·F L GrahamR Nairn
Oct 27, 1999·JAMA : the Journal of the American Medical Association·D K ShayL J Anderson
Apr 29, 2005·The New England Journal of Medicine·Ann R FalseyEdward E Walsh
Oct 6, 2006·Journal of Clinical Microbiology·Anna R ThornerDan H Barouch
Nov 17, 2006·The Journal of Infectious Diseases·Andrew T CatanzaroUNKNOWN Vaccine Research Center 006 Study Team
Feb 7, 2009·The New England Journal of Medicine·Caroline Breese HallPeter Szilagyi
Oct 13, 2011·Expert Review of Vaccines·Julia L Hurwitz
May 18, 2012·Journal of Virology·Jinyan LiuDan H Barouch
Jun 12, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Teresa R JohnsonJason G Gall
Jun 29, 2013·Current Opinion in Virology·Peter J Openshaw, Christopher Chiu
Aug 3, 2013·Pediatric Clinics of North America·Sharon H Gnagi, Scott A Schraff
Mar 7, 2014·Human Gene Therapy·Jort VellingaMenzo Havenga
Oct 21, 2014·Journal of Bioequivalence & Bioavailability·Chris StockmannCatherine Mt Sherwin

❮ Previous
Next ❯

Citations

May 18, 2016·Yonsei Medical Journal·Joo Young Kim, Jun Chang
Jun 18, 2016·The Journal of General Virology·Cindy Swett-TapiaSoumitra Roy
Mar 10, 2017·International Journal of Molecular Sciences·Emma Rey-Jurado, Alexis M Kalergis
May 21, 2017·Expert Review of Vaccines·Tonya VillafanaMark T Esser
Aug 8, 2017·International Journal of Molecular Sciences·Silvia VandiniMarcello Lanari
May 18, 2018·Human Vaccines & Immunotherapeutics·Jorge C G BlancoStefanie N Vogel
Oct 20, 2018·Minerva pediatrica·Anna C VittucciAlberto Villani
Oct 8, 2019·Expert Review of Vaccines·Iebe Rossey, Xavier Saelens
Jul 7, 2020·International Journal of Molecular Medicine·Ioannis N MammasDemetrios A Spandidos
Sep 12, 2019·BMJ : British Medical Journal·Hannah H Nam, Michael G Ison
Jan 30, 2019·Annual Review of Medicine·Barney S GrahamJason S McLellan
May 28, 2019·Frontiers in Microbiology·María José Altamirano-LagosAlexis M Kalergis
Dec 2, 2017·Human Vaccines & Immunotherapeutics·Sophie JanetMatthew D Snape
Nov 15, 2020·Vaccines·Carlotta BiagiMarcello Lanari
Dec 30, 2020·Vaccines·Nicholas W Lukacs, Carrie-Anne Malinczak
Mar 8, 2021·Vaccine·Jerome CustersUNKNOWN Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)
Aug 11, 2021·Viruses·Yogesh B NarkhedeEva-Maria Strauch

❮ Previous
Next ❯